Arrowhead Pharmaceuticals’ (ARWR) therapeutic candidate ARO-LUNG1 is being developed for an undisclosed disease of the lung. This is the first candidate to utilize the company’s TRiM platform. Arrowhead is aiming for a clinical trial application of the drug in 4Q18.
Arrowhead’s candidate ARO-HIF2 is under development for treating clear cell renal cell carcinoma (or ccRCCC). The drug is designed to inhibit the production of HIF-2a, which is associated with tumor progression and metastasis in ccRCC. The company has planned for a clinical trial application of the drug in 2019.
Currently, ARO-F12 is under development for the possible treatment of diseases mediated by F12, such as hereditary angioedema and thromboembolic disorders. F12 initiates the intrinsic coagulatory pathway. Arrowhead’s RNAi technology reduces the production of F12 and can thus prove to be a treatment option for hereditary angioedema and thromboembolic disorders.
Thrombosis is the formation of blood clots, which can primarily occur in veins and arteries and can obstruct blood flow.
Arrowhead entered into a licensing and collaboration agreement with Amgen (AMGN) in September 2016 under which the latter acquired the exclusive worldwide license to develop and commercialize ARO-LPA.
ARO-LPA reduces the production of apolipoprotein A. This protein is attributed to an increased risk of cardiovascular diseases.
Under the terms of the agreement, Arrowhead received an upfront payment of $35 million. Furthermore, Arrowhead is eligible to receive $617 million in the form of option payments, development, regulatory, and sales milestone payments.
Arrowhead Pharmaceuticals’ cash-per-share ratio stands at 0.88, while the ratios of its peers Gilead Sciences (GILD), Ignyta (RXDX), and Loxo Oncology (LOXO) stand at 21.74, 2.18, and 12.48, respectively.
Arrowhead Pharmaceuticals makes up ~0.01% of the Vanguard Health Care ETF’s (VHT) total portfolio holdings.
Charles Schwab (SCHW) reported its fiscal 2017 and 4Q17 results on January 17, 2018. Its EPS (earnings per share) stood at $0.41 in 4Q17.
Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.
The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.
Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.
Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.
As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.
Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.